{"id":"https://openalex.org/W47759073","doi":null,"title":"HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.","display_name":"HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.","publication_year":2006,"publication_date":"2006-10-01","ids":{"openalex":"https://openalex.org/W47759073","mag":"47759073","pmid":"https://pubmed.ncbi.nlm.nih.gov/17057271"},"language":"en","primary_location":{"id":"pmid:17057271","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17057271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Netherlands journal of medicine","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028909533","display_name":"J J de Langen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210139651","display_name":"Netherlands Pharmacovigilance Centre Lareb","ror":"https://ror.org/04fp8ns78","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210139651"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"J J de Langen","raw_affiliation_strings":["J.J. de Langen, The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. j.delangen@lareb.nl"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"J.J. de Langen, The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands. j.delangen@lareb.nl","institution_ids":["https://openalex.org/I4210139651"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073876435","display_name":"Eug\u00e8ne van Puijenbroek","orcid":"https://orcid.org/0000-0002-2236-1398","observed_orcids":["https://orcid.org/0000-0002-2236-1398"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E P van Puijenbroek","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.6083,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.85684019,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"64","issue":"9","first_page":"334","last_page":"8"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.6967999935150146,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.6967999935150146,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.09860000014305115,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.08969999849796295,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.9789999723434448},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.8579999804496765},{"id":"https://openalex.org/keywords/polyneuropathy","display_name":"polyneuropathy","score":0.9700000286102295},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9869999885559082},{"id":"https://openalex.org/keywords/hypercholesterolemia","display_name":"hypercholesterolemia","score":0.8679999709129333},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.871999979019165},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6990000009536743},{"id":"https://openalex.org/keywords/long-term-drug-exposure","display_name":"long-term drug exposure","score":0.8790000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9003655910491943},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.7915612459182739},{"id":"https://openalex.org/C104950815","wikidata":"https://www.wikidata.org/wiki/Q415607","display_name":"HMG-CoA reductase","level":4,"score":0.7847692966461182},{"id":"https://openalex.org/C2779901536","wikidata":"https://www.wikidata.org/wiki/Q945238","display_name":"Peripheral neuropathy","level":3,"score":0.6014554500579834},{"id":"https://openalex.org/C134651460","wikidata":"https://www.wikidata.org/wiki/Q3100717","display_name":"Reductase","level":3,"score":0.5965336561203003},{"id":"https://openalex.org/C2777300911","wikidata":"https://www.wikidata.org/wiki/Q692536","display_name":"Myopathy","level":2,"score":0.566975474357605},{"id":"https://openalex.org/C2779379848","wikidata":"https://www.wikidata.org/wiki/Q917069","display_name":"Rhabdomyolysis","level":2,"score":0.5517742037773132},{"id":"https://openalex.org/C2775892965","wikidata":"https://www.wikidata.org/wiki/Q1502312","display_name":"Polyneuropathy","level":2,"score":0.48030298948287964},{"id":"https://openalex.org/C2777320049","wikidata":"https://www.wikidata.org/wiki/Q2989497","display_name":"Hydroxymethylglutaryl-CoA reductase","level":5,"score":0.46164482831954956},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4027623236179352},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.40177077054977417},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33115673065185547},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.25237756967544556},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.220352441072464},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.08907514810562134},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0651545524597168},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006937","descriptor_name":"Hypercholesterolemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009426","descriptor_name":"Netherlands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010523","descriptor_name":"Peripheral Nervous System Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D011358","descriptor_name":"Product Surveillance, Postmarketing","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":4,"locations":[{"id":"pmid:17057271","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17057271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Netherlands journal of medicine","raw_type":"Journal Article"},{"id":"pmh:oai:pure.rug.nl:openaire_cris_publications/5ffb2f00-bf94-4201-b9f3-3f2ca49f9e16","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/11370/5ffb2f00-bf94-4201-b9f3-3f2ca49f9e16","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"de Langen, J J & van Puijenbroek, E P 2006, 'HMG-CoA-reductase inhibitors and neuropathy : reports to the Netherlands Pharmacovigilance Centre', The Netherlands Journal of Medicine, vol. 64, no. 9, pp. 334-338.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:rug:oai:pure.rug.nl:publications/5ffb2f00-bf94-4201-b9f3-3f2ca49f9e16","doi":null,"is_oa":false,"landing_page_url":"https://research.rug.nl/en/publications/5ffb2f00-bf94-4201-b9f3-3f2ca49f9e16","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"The Netherlands Journal of Medicine, 64(9), 334 - 338. van Zuiden Communications BV.","raw_type":"info:eu-repo/semantics/article"},{"id":"mag:47759073","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17057271","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W1969626317","https://openalex.org/W1983507730","https://openalex.org/W1991651591","https://openalex.org/W2000101702","https://openalex.org/W2000561057","https://openalex.org/W2029471511","https://openalex.org/W2031354797","https://openalex.org/W2051976808","https://openalex.org/W2058235270","https://openalex.org/W2059078444","https://openalex.org/W2086915651","https://openalex.org/W2087023389","https://openalex.org/W2108526545","https://openalex.org/W2115793895","https://openalex.org/W2118057359","https://openalex.org/W2131821370","https://openalex.org/W2132017042","https://openalex.org/W2140742150"],"related_works":["https://openalex.org/W1969626317","https://openalex.org/W2131821370","https://openalex.org/W71340138","https://openalex.org/W2017687352","https://openalex.org/W1980937155","https://openalex.org/W2093201495","https://openalex.org/W2115793895","https://openalex.org/W2565000186","https://openalex.org/W2473650797","https://openalex.org/W2061854870"],"abstract_inverted_index":{"The":[0,34,130,151],"number":[1,177],"of":[2,20,38,63,67,74,86,97,107,118,120,127,140,158,178,189,193],"patients":[3,179],"taking":[4,180],"HMG-CoA-reductase":[5,14,39,64,98,128,181],"inhibitors":[6,15,40,142],"for":[7,89,171],"hypercholesterolaemia":[8],"is":[9],"growing":[10],"rapidly.":[11],"Treatment":[12],"with":[13,94,124],"significantly":[16,145],"reduces":[17],"the":[18,68,71,77,95,125,138,169,175,190],"risk":[19,170],"cardiovascular":[21],"morbidity":[22],"and":[23,46,50,70,111,113,135,137,161],"mortality,":[24],"but":[25],"may":[26],"rarely":[27],"cause":[28],"serious":[29,36],"adverse":[30],"drug":[31],"reactions":[32],"(ADRs).":[33],"most":[35],"ADRs":[37,88],"are":[41,143],"musculoskeletal":[42],"symptoms":[43],"including":[44],"myopathy":[45],"myositis,":[47],"(life-threatening)":[48],"rhabdomyolysis":[49],"liver":[51],"failure.":[52],"Furthermore,":[53],"peripheral":[54,109,133,172],"neuropathy":[55,92,110,134],"might":[56],"also":[57],"occur,":[58],"especially":[59,165],"after":[60],"long-term":[61,166],"use":[62,96,126,139],"inhibitors.":[65,99,129],"Because":[66],"severity":[69],"relative":[72],"rarity":[73],"HMG-CoA-reductase-induced":[75],"neuropathy,":[76,108,132],"Netherlands":[78],"Pharmacovigilance":[79],"Centre":[80],"Lareb":[81,103],"has":[82],"analysed":[83],"its":[84],"database":[85],"reported":[87,148],"reports":[90,106,117,163],"concerning":[91],"associated":[93,123],"Until":[100],"June":[101],"2005,":[102],"received":[104],"17":[105],"polyneuropathy":[112,122,136],"in":[114,196],"addition":[115],"two":[116],"aggravation":[119],"existing":[121],"associations":[131],"hMg-CoA-reductase":[141],"statistically":[144],"more":[146],"often":[147],"to":[149,154],"Lareb.":[150],"average":[152],"time":[153],"onset":[155],"supports":[156],"conclusions":[157],"previous":[159],"studies":[160],"case":[162],"that":[164],"exposure":[167],"increases":[168],"neuropathy.":[173,197],"Considering":[174],"increasing":[176],"inhibitors,":[182],"health":[183],"care":[184],"professionals":[185],"should":[186],"be":[187],"aware":[188],"possible":[191],"role":[192],"these":[194],"drugs":[195]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}